Company DNIB Unwind Inc OTC Bulletin Board
Equities
BINDQ
US05548N1072
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Stephen Zale
CTO | Chief Tech/Sci/R&D Officer | 68 | 06-10-31 |
Tom Baker
IRC | Investor Relations Contact | - | - |
Neil Bander
PRN | Corporate Officer/Principal | - | - |
Corporate Officer/Principal | - | 16-07-23 | |
James L. Wright
PRN | Corporate Officer/Principal | 76 | 06-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Corporate Officer/Principal | - | 16-07-23 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 20,886,802 | 17,860,424 ( 85.51 %) | 0 | 85.51 % |
Company contact information
DNIB Unwind, Inc.
333 South Grand Avenue Suite 4100
90071, Los Angeles
+617-491-3400
http://bindtherapeutics.comSector
1st Jan change | Capi. | |
---|---|---|
+8.63% | 114B | |
+13.17% | 107B | |
-12.76% | 22.22B | |
-2.30% | 21.28B | |
-7.19% | 17.51B | |
-39.93% | 17.17B | |
+6.67% | 14.14B | |
+33.90% | 12.2B | |
-28.60% | 7.83B |
- Stock Market
- Equities
- BINDQ Stock
- BINDQ Stock
- Company DNIB Unwind Inc